Research News

Posted by Admin

On Wednesday, May 1, The Michael J. Fox Foundation (MJFF) presented a special breaking news edition of its Hot Topics in Parkinson’s Disease (PD) Research Seminar Series: “The Future of Trophic Factors,” to address recent disappointing clinical trial results from … Continue reading →

Posted by Admin

MJFF is today announcing the launch of three new funding programs focused on driving research toward transformative treatments and a cure for Parkinson’s disease (PD). Two programs will promote critical work on the promising therapeutic targets LRRK2 and Parkin, while … Continue reading →

Posted by Admin

In this podcast, MJFF Contributing Editor Dave Iverson reports on recent disappointing clinical trial results of San Diego-based biotech Ceregene’s trophic factor therapy CERE-120. For perspective on what the results mean for CERE-120 and trophic factors moving forward, Iverson speaks withWilliam … Continue reading →

Posted by Admin

Clumps of the protein alpha-synuclein are common to the brains of all people with Parkinson’s; unfortunately, there are more questions than answers as to whether and how alpha-synuclein plays a direct causative role in the disease. For this reason, scientists are investigating … Continue reading →

Posted by Admin

Encouraging news today for Parkinson’s patients, and in particular, for those experiencing the often debilitating motor fluctuations associated with the disease. Chelsea, Massachusetts-based biotech Civitas Therapeutics announced positive clinical trial results for their inhaled formulation of levodopa, called CVT-301. The … Continue reading →

Posted by Admin

Ceregene  announced disappointing results from its second Phase 2 trial of CERE-120, an experimental gene therapy treatment for Parkinson’s disease (PD). CERE-120 was designed to deliver neurturin, a specialized protein known as a trophic factor, into the brain. The hope … Continue reading →

Posted by Admin

Today we have moved tangibly closer to real results for patients. And I am optimistic that the momentum we’ve built over the past year in particular will continue to propel us forward to the goal we all want to reach … Continue reading →

Posted by Admin

You’ve probably heard about the benefits of getting enough of that vitamin D-boosting sunlight that can be in short supply during the winter months: It’s good for our bones and our immune system, and it fights depression. Vitamin D can … Continue reading →

Posted by Admin

Today’s Wall Street Journal reports on promising new research directions to treat dyskinesia (subscription required), the disabling side effect of long-term dopamine replacement therapy. “As they continue to wait for a cure, patients with Parkinson’s disease may soon see more … Continue reading →

Posted by Admin

Michael J. Fox Foundation (MJFF) Associate Director of Research Programs Maurizio Facheris, MD, MSc, is providing updates from this year’s American Academy of Neurology (AAN) Annual Meeting. In his second report from San Diego, Maurizio points to three more projects of … Continue reading →

Posted by Admin

You may have read in Bloomberg News that “Parkinson’s Patients May Be Harmed by Novel Treatment.” Here is our take. The reality is, the story surrounding alpha-synuclein is a complex one, and determining its role in Parkinson’s disease will require … Continue reading →

Posted by Admin

Michael J. Fox Foundation (MJFF) Associate Director of Research Programs Maurizio Facheris, MD, MSc, is providing updates from this year’s American Academy of Neurology (AAN) Annual Meeting. Here, Maurizio highlights three projects of note that he encountered in San Diego that … Continue reading →

Posted by Admin

MJFF and Addex Pharmaceuticals are announcing the next chapter in a continuing partnership around the development of dipraglurant, or “dipra,” for the treatment of dyskinesia, the debilitating side effect of long-term dopamine replacement therapy. A $1-million award from the Foundation will … Continue reading →

Posted by Admin

This week, more than 12,000 are expected to attend the American Academy of Neurology’s (AAN) Annual Meeting in San Diego, California, the largest international meeting of neuroscientists and neuroscience professionals worldwide. Our own Maurizio Facheris, MD, MSc, is among the … Continue reading →

Posted by Admin

Head of the Sanofi Genzyme R&D Center Rich Gregory, PhD, tells MJFF how his company is developing a critical research tool for use in a clinical trial at the University of California San Francisco. Gene therapy is a novel approach … Continue reading →

Posted by Admin

Today, Francis Collins, MD, PhD, the director of the National Institutes of Health, writes about critical “new insight” into a possible cause of Parkinson’s disease (PD). Collins’ blog centers around a report from a team of researchers at the Albert … Continue reading →

Posted by Admin

Israel-based biotech Neuroderm has announced positive results from a phase 1 safety and tolerability study into a levodopa/carbidopa “pump-patch” designed to continuously deliver both drugs subcutaneously. Usually levodopa/carbidopa regimens are taken orally, but the pump-patch, on the other hand, is … Continue reading →

Posted by Admin

Science has continually shown that people are less likely to develop Parkinson’s disease (PD) if they’ve been drinking plenty of coffee. Studies have also found that caffeine intake could help to mitigate some of the symptoms of PD after someone has … Continue reading →

Posted by Admin

On Tuesday, February 19, The Michael J. Fox Foundation (MJFF) hosted the first event of the year in its Hot Topics in Parkinson’s disease (PD) Research Seminar Series: “An Overview of Parkinson’s Disease Research.” The Webinar, which is now available on … Continue reading →

Posted by Admin

Parkinson’s is difficult to diagnose, and a big reason for this is that, as of yet, there is no objective test for determining if a person has the disease. Often, it can take years and visits to various specialists to … Continue reading →

Posted by Admin

Dysfunction in the cell, which is the basic unit of who we are, can be responsible for a variety of conditions such as psoriasis, cancer, and even neurological disorders such as Parkinson’s disease (PD). There are many processes critical to … Continue reading →

Posted by Admin

The Michael J. Fox Foundation (MJFF) is today announcing the launch of four new funding programs focused on driving forward research toward transformative treatments and a cure for Parkinson’s disease (PD). The new funding opportunities are open to both academic … Continue reading →

Posted by Admin

Clumps of the protein alpha-synuclein accumulate in the brains of all people with Parkinson’s disease (PD). Finding ways to break up, clear, or eliminate the toxicity of these clumps could go a long way toward finding a disease-modifying treatment for … Continue reading →

Posted by Admin

People with Parkinson’s disease who receive Deep Brain Stimulation (DBS) therapy in the early stages of the condition will benefit from a significant increase in quality of life, a revolutionary study from The New England Journal of Medicine has found. … Continue reading →

Posted by Admin

Development of their dyskinesia drug continues Michael J. Fox Foundation (MJFF) awardee Addex Therapeutics has announced a reorganization to increase focus on developing its clinical pipeline for rare and orphan diseases. The company remains committed to the development of dipraglurant … Continue reading →

Posted by Admin

MJFF launches $10,000 Data Challenge encouraging researchers to try and find out Smartphones carry basic sensors that can be used to measure and monitor many features of Parkinson’s disease (PD), which can in turn provide a window into a patient’s … Continue reading →

Posted by Admin

  In this episode of the ongoing video series, MJFF Contributing Editor Dave Iverson reports on the role that genetics is now playing in Parkinson’s disease (PD) research through the lens of the experience of one family in particular, that … Continue reading →

Posted by Admin

This is an important step toward finding a critically-needed drug for a largely untreated Parkinson’s symptom A clinical trial of a drug to treat cognitive dysfunction in Parkinson’s disease (PD) is today enrolling its first participants, an announcement that lends … Continue reading →

Posted by Admin

A certain kind of Parkinson’s disease (PD), called vascular parkinsonism, is thought to be caused by small strokes in the part of the brain associated with the motor symptoms of PD (the basal ganglia). This type of PD is often unresponsive … Continue reading →

Posted by Admin

Across the board, physicians agree: There’s no doubt that smoking is bad for you. But is it possible that there’s just something about a cigarette habit that might lower a person’s risk of developing Parkinson’s disease (PD)? Epidemiological data (in … Continue reading →

Posted by Admin

Physicians may one day be able to diagnose Parkinson’s disease (PD) by analyzing tissue from a person’s salivary glands, says a new study supported by The Michael J. Fox Foundation (MJFF) from Charles Adler, MD, PhD, a neurologist at the … Continue reading →

Posted by Admin

Today, an important milestone for the Parkinson’s Progression Markers Initiative (PPMI), as, for the first time, researchers have published a scientifically-reviewed paper using data culled from the study. The paper appears in Neurology, the medical journal of the American Academy of Neurology, and … Continue reading →

Posted by Admin

Last week, the research staff from MJFF reflected on some of the projects that they worked on this past year that they believe could have the greatest impact on the Parkinson’s patient community moving forward. Read on to hear directly … Continue reading →

Posted by Admin

Todd Sherer – MJFF CEO and Maurizo Facheris MD  answer some questions raised during the latest Hot Topics in Parkinson’s disease (PD) Research Seminar Series: “PD Research 2012: How Far We’ve Come and What Lies Ahead.” Does Parkinson’s begin in … Continue reading →

Posted by Admin

The protein leucine-rich repeat kinase 2, or LRRK2, is fast becoming a target of major interest for researchers looking to develop Parkinson’s disease (PD) drugs, for a couple of reasons: For one, mutations in the gene associated with LRRK2 are … Continue reading →

Posted by Admin

Positive clinical study results into a symptomatic treatment for Parkinson’s disease from Biotie Therapies, which targets a brain chemical called adenosine. And today, a quick addendum, as more positive trial results focused on adenosine were announced from another company – … Continue reading →

Posted by Admin

The way we talk says a lot about who we are and how we’re feeling. We may raise our voice when we’re angry, or soften our tone when feeling especially magnanimous. We may talk deliberately to make a point, or … Continue reading →

Posted by Admin

Today: In a phase 2b trial, Biotie’s drug tozadenant was found to significantly limit the “off periods” that many with Parkinson’s experience when taking levodopa, the gold standard therapy for the disease. Levodopa works by targeting a chemical in the … Continue reading →

Posted by Admin

Last month, researchers at the University of Pennsylvania published new evidence pointing to the role of protein misfolding in Parkinson’s disease. Today the Wall Street Journal reports on the emerging hypothesis that Parkinson’s and other neurodegenerative diseases may be caused at least … Continue reading →

Posted by Admin

This weekend, Fox Trial Finder reached its year-end goal of 10,000 registered volunteers – four months early! Thank you to all of the patients, loved ones and supporters who have stepped up to help speed better treatments and, ultimately, a … Continue reading →

Posted by Admin

In spring 2009, personal genetics company 23andMe, a Michael J. Fox Foundation research partner, announced an effort to recruit 10,000 people with Parkinson’s for genetic research in PD. Today the23andMe PD Research Community has become the largest single Parkinson’s community … Continue reading →

Posted by Admin

The obstacles to bringing new Parkinson’s disease (PD) drugs to market are many, and they span all stages of the drug development pipeline. On average, the time it takes to bring one new drug to market is 15-30 years, with … Continue reading →

Posted by Admin

The path to new drugs often begins with a Eureka moment — when an academic working in a lab discovers a specific molecular process in our cells that seems to be causing a disease or its symptoms. It’s a key … Continue reading →

Posted by Admin

It’s been a big year for PPMI. In the ongoing search to better understand what’s happening in the body prior to the motor symptoms of PD, the study is launching a new arm that will include adding a pre-motor cohort. … Continue reading →

Posted by Admin

One hypothesis in the field of Parkinson’s disease (PD) research is that the alpha-synuclein protein implicated in PD might spread throughout the brain. Today, the latest paper supporting this hypothesis was published in the journal Science by Virginia Lee, PhD, MBA, and her … Continue reading →

Posted by Admin

We all know that exercise is good for you. After all, its benefits to mind and body are widely acknowledged, and it may even help you to build bigger biceps. But did you know that working out might also help … Continue reading →

Posted by Admin

Over the past few months, one particular Alzheimer’s disease (AD) drug target has repeatedly been in the news for all the wrong reasons: a protein called beta amyloid. Many in the field of AD research have hypothesized that the accumulation … Continue reading →

Posted by Admin

Last week, The Michael J. Fox Foundation (MJFF) hosted a workshop to delve deeper into understanding how specific mutations in a gene called glucocerebrosidase (GBA) might cause Parkinson’s disease (PD). The group met in New York to make recommendations as to … Continue reading →

Posted by Admin

Several years ago, Jim Surmeier, PhD, of Northwestern University, made an important discovery inspired by ongoing work in the lab: He found that hyperactive calcium channels (which are targeted by certain high blood pressure medications) might also stress dopamine neurons, leading … Continue reading →

Posted by Admin

It’s long been believed that there is a link between exposure to pesticides and developing Parkinson’s disease (PD), and recent studies have provided plenty of data to back this idea. This week, newly-released results into an herbicide called paraquat show … Continue reading →

Posted by Admin

BOXING while naming the ways to cook an egg might sound ludicrous to some, but it’s one of the ways a Frenchs Forest woman with Parkinsons is regaining control of her life. Pat Alberts, 60, is undertaking a new course … Continue reading →

Posted by Admin

American scientists Robert Lefkowitz and Brian Kobilka were today awarded the Nobel Prize in Chemistry for discoveries surrounding receptors that play a role in certain medical conditions, including Parkinson’s disease (PD). Studies into so-called G-protein-coupled receptors (GPCRs) are critical to drug development: About half of … Continue reading →

Posted by Admin

In 2012, The Michael J. Fox Foundation is seeing the impact of many years of investment in breakthroughs for both symptomatic and disease-modifying treatments for Parkinson’s disease. Through your help you can keep these treatments moving forward. Every advance brings … Continue reading →

Posted by Admin

PD warrior has been described as a ‘game changer’ in the way that Parkinson’s disease can be managed. Exercise has long been recognised for its therapeutic benefits in maintaining mobility in function. However in the last few years there has … Continue reading →

Posted by Admin

Prana Biotechnology Limited (NASDAQ: PRAN) (ASX: PBT) announced today that its lead compound in development for Parkinson’s disease (PD), PBT434, had progressed successfully though a series of preclinical development studies used to assess the suitability of a candidate compound for … Continue reading →

Posted by Admin

Four and a half months after its official launch, Fox Trial Finder is closing in on its year-end goal of 10,000 registered volunteers! Fox Trial Finder is MJFF’s web-based clinical trials matching tool and has been embraced by the PD … Continue reading →

Posted by Admin

  Parkinson’s Victoria and Monash University are excited to announce a new program for people with Parkinson’s. The ESSENCE Research Program is FREE to join and will help you to live better with Parkinson’s. Our mindfulness expert Dr Craig Hassed … Continue reading →

Posted by Admin

Emerging evidence over the past 15 years has led researchers to believe that genetics plays a far greater role in Parkinson’s disease (PD) than was once thought. Today, scientists are digging deeper than ever before, with the hope of translating … Continue reading →

Posted by Admin

There are all kinds of benefits to getting enough sleep: It’s good for your heart, it can help to reduce stress, it may even prevent cancer. And of course, it’s good for your brain too. This week, a study from … Continue reading →

Posted by Admin

Cognitive dysfunction is a troublesome reality for many people living with Parkinson’s disease (PD). Symptoms can range from slowness of thinking or difficulty organizing and sequencing one’s thoughts to memory loss to the eventual onset of dementia Even more troubling … Continue reading →

Posted by Admin

Dr. Graham Hughes is a geriatrician at St. Vincent’s University Hospital here in Dublin, so you might say he knows a bit about what it means to enter into the late(r) stages of life. Actually, the title to today’s blog … Continue reading →

Posted by Admin

  Doctors and patients have welcomed the introduction of a new Parkinson’s disease drug to the Australian market. The Federal Government has added Azilect, also called rasagiline, to the Pharmaceuticals Benefits Scheme (PBS). The drug, taken in tablet form, reduces … Continue reading →

Posted by Admin

Looking to keep your wits about you? Recent studies suggest that by adopting an “active cognitive lifestyle,” individuals may be able to slow cognitive decline. Add to that studies performed by game theorists and anecdotal evidence, tasks such as puzzles, brain games, and trivia … Continue reading →

Posted by Admin

Read on to learn more about the benefits of exercise, diet, and other forms of alternative ways to manage PD. What is the Big and Loud Program? Big and Loud is a rehabilitation and home exercise program designed by a … Continue reading →

Posted by Admin

While we don’t yet understand how, research has indicated that caffeine may have a neuroprotective effect—meaning that people who are regular coffee drinkers are less likely to develop Parkinson’s disease (PD). But a recent study published in the August 1 … Continue reading →

Posted by Admin

In this episode of the ongoing video series, Dave Iverson reports on the search for biomarkers for Parkinson’s disease (PD), and The Michael J. Fox Foundation’s major initiative driving this search — The Parkinson’s Progression Markers Initiative (PPMI). Biomarkers are … Continue reading →

Posted by Admin

At last month’s Movement Disorder Society’s Annual Congress, a clinical study of isradipine (brand name Dynacirc CR), a drug currently approved to treat high blood pressure, was awarded Blue Ribbon status for work investigating the drug’s potential as a disease-modifying … Continue reading →

Posted by Admin

According to a report in the New York Times, the European Medicines Agency has recommended that gene therapy be approved for use in a rare disease called lipoprotein lipase deficiency. Should the European Commission follow this recommendation, as it usually … Continue reading →

Posted by Admin

Scientists have called for a ban on a pesticide with links to Parkinson’s disease and have warned more people may get sick. To watch the video Click Here To read the full Transcript STEVE CANNANE, PRESENTER: There are calls to … Continue reading →

Posted by Admin

$45-million, five-year observational clinical study, sponsored by The Michael J. Fox Foundation and funded in Australia by the Shake It Up Australia Foundation, will seek biomarkers of Parkinson’s disease. Macquarie Neurology, a specialist neurology practice located at Macquarie University, and … Continue reading →

Posted by Admin

Last week The Michael J. Fox Foundation for Parkinson’s Research hosted the third call in our ongoing Seminar Call Series on Hot Topics in PD Research, focusing on holistic approaches to treating Parkinson’s disease. Hosted by MJFF CEO Todd Sherer, … Continue reading →

Posted by Admin

Australian scientists are confident new brain stimulation research will help long-term stroke and Parkinson’s disease patients speak again. The new approach, pioneered by Professor Bruce Murdoch from the University of Queensland, uses magnetic pulses to stimulate damaged areas of the … Continue reading →

Posted by Admin

MJFF awardee Civitas Therapeutics today announced that they have initiated a clinical trial for an inhaled formulation of levodopa, the gold standard therapy to treat the motor symptoms of Parkinson’s disease (PD). To date, the practical way that levodopa has been … Continue reading →

Posted by Admin

For many, the decision to participate in genetic research is not a trivial one. But for Gary Schmitz, he didn’t think twice. “For me,” he says, “the question was why wouldn’t you want to contribute?” Not long after The Michael … Continue reading →

Posted by Admin

Doctors will soon be able to identify the early stages of dementia in the 40 per cent of Parkinson’s Disease (PD) patients in Australia who later develop the illness. Researchers at Monash University, in collaboration with the University of Canterbury … Continue reading →

Posted by Admin

Austria-based biotech and Michael J. Fox Foundation awardee AFFiRiS AG today announced the launch of an early stage clinical trial of a first-of-its-kind vaccine approach to treating Parkinson’s disease, called PD01. The AFFiRiS vaccine targets alpha-synuclein, a protein whose clumping is present … Continue reading →

Posted by Admin

Recently, biotech company Ceregene announced evidence of increased levels of the trophic factor neurturin in the brain, for four-plus years following CERE-120 gene therapy to treat Parkinson’s disease (PD). In PD, gene therapy approaches aim to limit the loss of dopamine neurons … Continue reading →

Posted by Admin

  Treating Parkinson’s Disease sufferers with the right drug dose at the right time is often an inexact science. But a wrist-worn device which collects data on a patient’s symptoms is allowing practitioners to improve treatment. The device, based on … Continue reading →

Posted by Admin

For people living with Parkinson’s disease, the future is full of obstacles and uncertainty. This is the sole reason the second most prevalent neuro-degenerative disease that affects about 1 million people in the U.S., and 5 million worldwide has researchers … Continue reading →

Posted by Admin

By the time a person is diagnosed with Parkinson’s, the disease is already well developed – typically an individual has already lost around 80 percent of their dopamine neurons. Understanding the disease process taking place before symptoms occur could have … Continue reading →

Posted by Admin

Colonoscopies are one of the best ways to screen for cancer. Now, a new study from Rush University Medical Center finds they might also be a tool for predicting Parkinson’s disease (PD). Analyzing tissue taken during colonoscopies, researchers found the … Continue reading →

Posted by Admin

  Today, The Michael J. Fox Foundation launches its new video series “The Parkinson’s Minute”, featuring Patient Council member and public broadcasting producer Dave Iverson. In this first edition, Iverson reports that Americans with advanced Parkinson’s disease (PD) who struggle … Continue reading →

Posted by Admin

Sanofi announced today that it has entered into a collaboration with the Michael J. Fox Foundation (MJFF) to conduct a clinical trial to assess the safety and tolerability of AVE 8112, a Sanofi PDE4 inhibitor – phosphodiesterase type 4 inhibitor … Continue reading →

Posted by Admin

How your brain processes dopamine may define whether you’re more prone to bust your can or sit back and slack. This, according to a new study from Harvard Medical School and Vanderbilt University published in a recent issue of the … Continue reading →

Posted by Admin

In April, more than 30 world leaders in Parkinson’s disease (PD) research gathered in New York City for The Michael J. Fox Foundation’s (MJFF) annual Scientific Advisory Board (SAB) meeting.  A top theme throughout the two-day meeting: the genetics of … Continue reading →

Posted by Admin

Researchers funded by The Michael J. Fox Foundation (MJFF) have identified the best clinical scale for measuring patient response to therapies to treat dyskinesia, the debilitating, uncontrollable movements that are often a side effect of Parkinson’s disease (PD) drugs. The … Continue reading →

Posted by Admin

In spring 2009, personal genetics company 23andMeannounced that it would recruit 10,000 people with Parkinson’s to contribute DNA for research to illuminate the role of genetics in PD. Three years later, 7,500 people with Parkinson’s across 49 U.S. states and 26 … Continue reading →

Posted by Admin

FOX TRIAL FINDER When you participate in research, you give something money can’t buy. Fox Trial Finder opens the door to your opportunity to make a priceless contribution in the search for a cure. Parkinson’s patients and their loved ones … Continue reading →

Posted by Admin

A recent study published in the journal Neurology found that diets high in flavonoid-rich foods may lower Parkinson’s disease (PD) risk in men. Foods high in flavonoids — compounds that occur naturally in some plants — include berries, red wine, … Continue reading →

Posted by Admin

Study of Antidepressants in Parkinson’s disease or SAD-PD, a first-of-its-kind study published today in the medical journal Neurology, has found that two common antidepressants ease depression in people with Parkinson’s disease (PD) without aggravating motor symptoms. The drugs tested in … Continue reading →

Posted by Admin

Recently, Todd Sherer, CEO of The Michael J. Fox Foundation (MJFF), Brian Fiske, vice president of research programs at MJFF, and Emily Drabant,23andMe’s research manager for its Parkinson’s community, sat down and took stock of the recent advances in Parkinson’s research. … Continue reading →

Posted by Admin

Todd Sherer, PhD, is the Chief Executive Officer of The Michael J. Fox Foundation for Parkinson’s Research (MJFF). In this role he directs the organisation’s research strategy while providing day-to-day management and oversight of the Foundation. In this second edition … Continue reading →

Posted by Admin

Understanding the genetics of Parkinson’s disease (PD) could be a total game changer in developing new treatments for the disease. Especially when it comes to two genetic targets in particular: LRRK2, the most common genetic mutation in PD, and alpha-synuclein, … Continue reading →

Posted by Admin

Many people with Parkinson’s disease (PD) have trouble sleeping. In addition to a general difficulty falling and then staying asleep, some deal with restless leg syndrome (an uncontrollable urge to move the legs during sleep). Others experience intense nightmares. Some … Continue reading →

Posted by Admin

Today, good news in the search for a treatment for dyskinesia, the uncontrollable movements that are so often a disabling side effect of Parkinson’s disease medication. Swiss biotech and Michael J. Fox Foundation awardee Addex Therapeutics has announced positive results … Continue reading →

Posted by Admin

A $10 million research centre will be established in Brisbane to study and treat diseases of the brain like Parkinson’s and epilepsy.

Posted by Admin

It’s long been understood that the motor symptoms of Parkinson’s disease (PD) stem from a loss of dopamine-producing cells in the brain. But the past few years have added weight to an emerging hypothesis in the field: that the central … Continue reading →

Posted by Admin

AUSTRALIAN researchers have developed a novel technique that tracks proteins “behaving badly” and may lead to new treatments for brain disease. The team believes the discovery could help in the development of drugs to treat diseases such as Alzheimer’s, Parkinson’s … Continue reading →

Posted by Admin

While levodopa is the gold standard therapy for Parkinson’s disease (PD), current delivery methods have their limitations. Many patients who take it experience “off” periods, when the medication’s effects wear off before they are ready to take their next dose, leaving … Continue reading →

Posted by Admin

Millions of people suffer from Parkinson’s disease, a disorder of the nervous system thataffects movement and worsens over time. As the world’s population ages, it’s estimated that the number of people with the disease will rise sharply. Yet despite several … Continue reading →